Abstract:Background Pulmonary arterial hypertension is a fatal disease characterised by progressive narrowing of pulmonary arterioles, driven by aberrant cellular proliferation. Identification of key pathways in disease pathogenesis is required for the development of new-targeted therapies. We have previously reported tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) immunoreactivity within pulmonary vascular lesions from patients with idiopathic pulmonary arterial hypertension and animal models. Since TRAIL induces endothelial cell apoptosis and smooth muscle cell proliferation, we hypothesised that TRAIL is an important driver of disease in pulmonary arterial hypertension. Methods We characterised the expression of TRAIL in human and rodent pulmonary arterial hypertension and determined the effects of TRAIL on pulmonary artery smooth muscle cells (PASMCs) in vitro. Using genetic deletion, pharmacological overexpression, antibody blockade, and bone marrow transplant (BMT) chimera experiments we determined the direct pathogenic role of TRAIL in three independent rodent models of pulmonary arterial hypertension. We then tested the efficacy of inhibiting TRAIL in halting or regressing established disease in two preclinical models. Terminal phenotyping included cardiac catheterisation, echocardiography, and pulmonary vascular immunohistochemistry. Findings TRAIL mRNA and protein expression was upregulated in PASMCs from patients with pulmonary arterial hypertension. In vitro, TRAIL was a mitogen for PASMCs. TRAIL-deficient mice were protected from both hypoxia-induced and diet-induced pulmonary arterial hypertension. Antibody blockade prevented rats from developing toxin-induced disease. In BMT chimeras, only mice with expression of TRAIL restricted to tissue developed pulmonary arterial hypertension. In rodents with established pulmonary arterial hypertension, an anti-TRAIL antibody reversed pulmonary vascular remodelling, through reducing proliferation and inducing apoptosis, improved pulmonary haemodynamics, and significantly improved survival. Interpretation Our studies are the first to determine the importance of TRAIL in the pathogenesis of pulmonary arterial hypertension and demonstrate its potential for translation into a novel therapeutic target Funding British Heart Foundation.

The expression and clinical significance of TRAIL in pulmonary artery hypertension

Serum levels of tumor necrosis factor-related apoptosis-inducing ligand correlate with the severity of pulmonary hypertension

TRAIL and Cancer Therapy

Inhibition of Tumor Necrosis Factor–related Apoptosis-Inducing Ligand (TRAIL) Reverses Experimental Pulmonary Hypertension

Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand is A Novel Therapeutic Target in Pulmonary Arterial Hypertension

The Potential Molecular Mechanism of Overexpression of Upa, IL-8, MMP-7 and MMP-9 Induced by TRAIL in Pancreatic Cancer Cell.

Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension

The Clinical Value of Plasma Soluble Tumour Necrosis Factor Related Apoptosis Inducing Ligand Level in Patients with Systemic Lupus Erythematosus

Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.

Preliminary study of tumor necrosis factor-related apoptosis inducing ligand gene expression in patients with primary biliary cirrhosis

The Expression of TRAIL in Psoriatic Patients and Healthy Subjects

A Preliminary Study on the Relationship Between the Levels of Plasma TRAIL and DR5 and Acute Coronary Syndrome

Experssion and Significance of TRAIL and Its Receptors in Rectal Cancer

Expressions of TRAIL in breast cancer

Expression of TRAIL and Its Receptors in Primary Hepatic Carcinoma

Change in expression of tumor necrosis factor receptor-associated factor 6 in lung tissues of rats with pulmonary hypertension

Plasma level of soluble tumor necrosis factor-related apoptosis-inducing ligand in patients with primary biliary cirrhosis: expression and clinical significance

Expression of TRAIL in esophageal squamous cell cancer and the surrounding tissues

Increased TRAIL Expression in Peripheral Blood Mononuclear Cells from Patients with Primary Immune Thrombocytopenia and Its Clinical Significance

A Novel Biomarker for Prognostic Assessment and Risk Stratification of Acute Pulmonary Embolism

Preliminary Clinical Measurement of the Expression of Tnf-Related Apoptosis Inducing Ligand in Patients with Ankylosing Spondylitis